Abstract
Objectives Pharmacogenomic testing (PGX) implementation is rapidly expanding, including pre-emptive testing funded by health systems. PGX continues to develop an evidence base that it saves money and improves clinical outcomes. Identifying the potential impact of pre-emptive testing in specific populations may aid in the development of a business case. Methods We utilized a software tool that can evaluate patient drug lists and identified groups of patients most likely to benefit from implementation of a PGX testing program in a major medical system population. Results Medication lists were obtained for sixteen patient groups with a total of 82 613 patients. The percent of patients in each group with testing 'Recommended', 'Strongly recommended', or 'Required' ranged from 12.7% in the outpatient pediatric psychiatry group to 75.7% in the any adult inpatient age >50 years group. Some of the highest yield drugs identified were citalopram, simvastatin, escitalopram, metoprolol, clopidogrel, tramadol, and ondansetron. Conclusion We demonstrate a significant number of patients in each group may have benefit, but targeting certain ones for pre-emptive testing may result in the initial highest yield for a health system.
Original language | English (US) |
---|---|
Pages (from-to) | 91-95 |
Number of pages | 5 |
Journal | Pharmacogenetics and Genomics |
Volume | 30 |
Issue number | 5 |
DOIs | |
State | Published - Jul 1 2020 |
Keywords
- pharmacogenetics
- pharmacogenomics
- populations actionable
- pre-emptive testing
ASJC Scopus subject areas
- Genetics(clinical)
- Genetics
- Molecular Medicine
- Molecular Biology
- Pharmacology, Toxicology and Pharmaceutics(all)